Skip to main content
Clinical Trials/NCT05076734
NCT05076734
Completed
Not Applicable

Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Maternal Peripheral Blood: N o Return of Results -Luna Collection

Luna Genetics1 site in 1 country157 target enrollmentJune 12, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pregnancy Related
Sponsor
Luna Genetics
Enrollment
157
Locations
1
Primary Endpoint
Fetal Cell Recovery and genetic analysis
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The purpose of the overall study is to develop improved methods for recovery of fetal cells from the mother's blood in order to develop a clinically useful form of cell-based, diagnostic, noninvasive prenatal testing (NIPT). Luna Genetics will analyze blood samples from healthy pregnant women. A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.

Registry
clinicaltrials.gov
Start Date
June 12, 2020
End Date
December 30, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Sponsor
Luna Genetics
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18years or older

Exclusion Criteria

  • Language barrier (non-English speaking and no adequate interpreter)
  • Maternal age of less than 18 years
  • Higher order multiple pregnancy (triplet or greater)
  • Not currently pregnant

Outcomes

Primary Outcomes

Fetal Cell Recovery and genetic analysis

Time Frame: 2 months

Outcome 1 is the number of cells identified as fetal by microscopic staining. This can be converted to units based on volume. If 40 mL of blood is collected and f8 cells are designated as fetal based on microscopic staining, the results can be tabulated as follow: So a result is 8 cells are identified as fetal from one blood draw. This equals 0.2 cells identified per mL of maternal blood. If two or fewer cells are obtained, a blood redraw will be requested from the patient.

Redraw for Fetal Cell Recovery and genetic analysis

Time Frame: 2 months

Outcome measure 2 is the number of cells that yield high quality next generation sequencing data suitable for determining copy number across the entire genome. So if 4 of the 8 cells above gave high quality data, the outcome would be 4 cells with high quality copy number data from one blood draw which equals 0.10 high quality cell / mL of mother's blood.

Study Sites (1)

Loading locations...

Similar Trials